story of the week
ESMO 2021: Benefits of Abiraterone Confirmed in Metastatic and High-Risk Nonmetastatic Prostate Cancer
Findings of STAMPEDE and PEACE-1 suggest abiraterone should be part of standard of care in both settings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.